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Objective: Bone morphogenetic protein 2 (BMP-2, encoded by BMP2) and Indian hedgehog protein (IHH,
encoded by IHH) are well known regulators of chondrogenesis and chondrogenic hypertrophy. Despite
being a potent chondrogenic factor BMP-2 was observed to induce chondrocyte hypertrophy in osteo-
arthritis (OA), growth plate cartilage and adult mesenchymal stem cells (MSCs). IHH might induce
chondrogenic differentiation through different intracellular signalling pathways without inducing sub-
sequent chondrocyte hypertrophy. The primary objective of this study is to test the efﬁcacy of direct
BMP2 and IHH gene delivery via bone marrow coagulates to inﬂuence histological repair cartilage quality
in vivo.
Method: Vector-laden autologous bone marrow coagulates with 1011 adenoviral vector particles
encoding BMP2, IHH or the Green ﬂuorescent protein (GFP) were delivered to 3.2 mm osteochondral
defects in the trochlea of rabbit knees. After 13 weeks the histological repair cartilage quality was
assessed using the ICRS II scoring system and the type II collagen positive area.
Results: IHH treatment resulted in superior histological repair cartilage quality than GFP controls in all of
the assessed parameters (with P < 0.05 in ﬁve of 14 assessed parameters). Results of BMP2 treatment
varied substantially, including severe intralesional bone formation in two of six joints after 13 weeks.
Conclusion: IHH gene transfer is effective to improve repair cartilage quality in vivo, whereas BMP2
treatment, carried the risk intralesional bone formation. Therefore IHH protein can be considered as an
attractive alternative candidate growth factor for further preclinical research and development towards
improved treatments for articular cartilage defects.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.A.F. Steinert, Department of
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Available cell based treatments for articular cartilage repair fail
to persistently restore hyaline articular cartilage in vivo1. One of the
reasons for this failure, is an insufﬁcient chondrogenic differentia-
tion of transplanted or local multipotent cells2. To overcome this
limitation, the delivery of relevant factors has been proposed as
treatment option2. Several growth factors have been shown to
stimulate chondrogenesis, including members of the transforming
growth factor (TGF)-b superfamily2,3. One member of this family,
bone morphogenetic protein 2 (BMP-2, encoded by BMP2), is
emerging as a potent inducer of chondrogenesis in vitro4e6 and
in vivo7e9. BMP-2 is affecting gene expression via members of the
SMAD protein family or mitogen-activated protein (MAP) kinase
pathways after binding to BMP type I and type II receptors at the
cell membrane10,11. However, along with other factors, it wastd. All rights reserved.
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growth plate cartilage and adult mesenchymal stem cells (MSCs)
in vitro2,6,12. While the induction of intralesional hypertrophy and
bone formation in cartilage defects by BMP-2 was discussed pre-
viously, there is only limited data on this topic to date2.
To achieve persistent hyaline cartilage regeneration, the stim-
ulation of chondrogenic differentiation using different, non-
hypertrophic, pathways is desirable2. The growth plate regulating
Indian hedgehog protein (IHH, encoded by IHH) is an attractive
candidate growth factor, which is observed to effectively induce
chondrogenesis of MSCs in vitro, without driving chondrocyte hy-
pertrophy13,14. IHH is affecting gene expression via Gli transcription
factors14. Although BMP signalling might affect the IHH gene
expression, no extensive activation of BMP signalling by IHH is
described to date15. Despite of promising results in vitro, it is not
known if IHH is capable of inducing chondrogenesis in cartilage
defects in vivo.
The objective of this proof of concept study was to determine if
IHH is capable to improve cartilage repair quality in vivo and thus
resembles an attractive alternative growth factor candidate. Spe-
ciﬁcally, we hypothesized, that direct adenoviral gene transfer of
IHH or BMP2 into osteochondral defects, using autologous vector-
laden bone marrow coagulates, results in higher histological
repair cartilage quality and higher type II collagen deposition, than
the transfer of GFP (encoding for the non-chondrogenic green
ﬂuorescent protein). Bone marrow coagulates in combination with
adenoviral vectors were previously shown to be an efﬁcient direct
gene delivery system for the treatment of osteochondral defects16,17.
Methods
Experimental animals, allocation, outcomes and comparisons
This controlled small-animal experiment was performed as
approved by the Institutional Review Board of the Julius-
Maximilians-University of Würzburg, Germany. Reporting is
guided by the ARRIVE (Animal Research: Reporting of In Vivo Ex-
periments) guidelines18. Ten female, skeletally mature New Zea-
land White Rabbits (with a mean weight of 3.11 kg ± 0.22 kg
standard deviation; Charles River, Kißlegg, Germany) wereFig. 1. One-stage gene transfer procedure and defect morphology at day 0. Aspiration of
adenoviral vector particles carrying the respective gene (either IHH, BMP2 or GFP) into each w
3.2 mm diameter osteochondral defect (b). The vector-laden bone marrow coagulate was
additional ﬁxatives (c, d). Capsule, subcutaneous tissue and skin were closed in layers and
staining of the osteochondral defect after press-ﬁt implantation of the autologous vector-lad
on the right side of the picture, while the vector-laden bone marrow coagulate is depicted o
altered the coagulate surface. Bar representing 500 mm (e).randomly assigned to the respective groups: n ¼ 4 animals in the
IHH and n ¼ 3 in the BMP2 treatment groups, as well as n ¼ 3 in the
GFP control group. All animals received one osteochondral defect in
each of their knees. In a one-stage procedure the defects were ﬁlled
with an autologous bone marrow coagulate in combination with
adenoviruses carrying complementary DNA (cDNA) of the respec-
tive transgene [Fig. 1(a)e(d)]. According to the allocation of the
animal, the same gene was transferred in both knees, thus each
animal contributed two observations. One additional animal was
used to characterize themorphology of the treated lesion at the day
of surgery [Fig. 1(e)].
Histological scoring, using the overall assessment parameter of
the semiquantitative International Cartilage Repair Society II his-
tological scoring system (ICRS II)19 and type II collagen deposition
(assessed by immunohistomorphometry) were designated as pri-
mary outcomes. Further, we assessed the remaining ICRS II pa-
rameters, the type X collagen deposition (as a marker of
chondrocyte hypertrophy) and the type I collagen deposition (as a
marker of ﬁbrocartilage). The BMP2 and IHH treated animals where
compared to GFP controls at 13 weeks after surgery, which has
previously been reported to be an appropriate time to evaluate
long-term repair results in rabbits20.
Adenoviral vectors
The ﬁrst-generation, early region 1 and 3 (E1 and E3) deleted,
serotype ﬁve adenoviral vectors carrying BMP2, IHH or GFP cDNA
were previously generated and ampliﬁed as described before6,21.
Suspensions of recombinant adenovirus were prepared by ampli-
ﬁcation in human embryonic kidney 293 cells followed by puriﬁ-
cation using three consecutive caesium chloride gradients21. Viral
titres were estimated to be between 1012 and 1013 particles/ml by
optical density at 260 nm and standard plaque assay21.
Intervention, gene transfer system and animal care
Autologous bone marrow coagulates containing adenoviral
vectors, were used as gene transfer system, as described and
characterized before16. Brieﬂy, animals received 10 mg xylazine
(Bayer Vital, Leverkusen, Germany) and 200 mg ketamineautologous bone marrow, transfer into wells of a 96-well plate and addition of 1011
ell (a). Exposure of the femoral trochlea using a medial arthrotomy and generation of a
obtained from the 96-well plate using forceps and implanted into the lesion without
the procedure was repeated for the contralateral knee (not shown). Type II collagen
en bone marrow coagulate. Native adjacent cartilage and subchondral bone is depicted
n the left side. Note, that ﬁxation and demineralization was necessary, which may have
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isoﬂurane (Abbott, Wiesbaden, Germany) to maintain anaesthesia.
One ml of metamizol (Ratiopharm, Ulm, Germany) i.m. was
administered perioperatively and 5 gtt of tramadol (Ratiopharm)
per 500 ml of drinking water was given for the ﬁrst 5 days after
surgery. Infection prophylaxis was performed using an i.m. injec-
tion of procaine-benzylpenicillin (60.000 IU/kg; Pﬁzer, Karlsruhe,
Germany) perioperatively. Bone marrow was aspirated from the
iliac crest under aseptic conditions [Fig. 1(a)]. 200 ml aliquots were
each mixed with 1  1011 adenoviral vector particles carrying the
respective gene in a generic 96-well culture plate. Aliquots were
allowed to form coagulates for 5 min at room temperature. Under
sterile conditions, femoral trochleae were exposed by medi-
opatellar arthrotomies. Central osteochondral defects were created
perpendicular to the surface using a 3.2 mm diameter drill bit
aiming for a depth of 5 mm [Fig. 1(b)]. The vector-laden bone
marrow coagulates were then press-ﬁtted into the lesions. No
additional ﬁxative was necessary [Fig. 1(d)]. Capsule, subcutaneous
tissue and skin were sutured separately. All animals were allowed
to move freely in their cage at all times after surgery. A 12 h night-
day cycle was simulated in the animal care facility.
After 13 weeks, animals received a 10 mg xylazine and 200 mg
ketamine i.m. to induce deep anaesthesia before administration of
15 mg tetracain-hydrochloride, 150 mg mebezonium-iodide and
600 mg embutramide (T61, Intervet, Unterschleißheim, Germany)
into the ear-vein for euthanasia. Femoral diaphyses were cut
proximally of the trochlea to obtain the distal femurs. After com-
plete removal of the joint capsule, the epicondyles were removed
using a chisel.Processing of histological specimens
The distal femurs were ﬁxed in neutralized 4% para-
formaldehyde for 11 weeks, demineralized in Calci-Clear Rapid
(National Diagnostics, Atlanta, Georgia, USA) and embedded in
Parafﬁn. Embedded specimens were stored at 20C. Four repre-
sentative 4 mm slides from the center of the defects (deﬁned by a
diameter >80% of the drill bit diameter, corresponding to >2.6 mm)
were obtained. For each knee, one haematoxylin eosin (HE), one
type II collagen (as a marker of hyaline cartilage20) one type I
collagen (as a marker of ﬁbrocartilage20) and one type X collagen
staining (as a marker of chondrocyte hypertrophy6) was prepared
(Table I). Negative controls with equally concentrated mouse serum
replacing the antibodies were carried out along with each batch.
For antibody detection, a streptavidin-biotin interaction based kit
using alkaline phosphatase to catalyse fast red was used (Super-
Sensitive TM Link-label IHC Detection System, BioGenex, Fremont
CA, USA). Endogenous alkaline phosphatase was blocked by addi-
tion of levamisole hydrochloride (Sigma, St. Louis MO, USA).
Photomicrographs were obtained in a square scanning pattern,
using a Carl Zeiss Axioskop microscope with a 10 objective, an
AxioCam ICc 1 camera and the Axiovision 40 software Version
4.7.2.0 (Carl Zeiss MicroImaging, Jena, Germany). Images wereTable I
Targets, primary antibodies, recommended antibody concentrations and antigen
immunohistochemistry
Target Antibody
Type II collagen
(Collagen alpha-1(II) chain)
Monoclonal mouse IgG1
(AF5710, Acris Antibodies, San Diego CA, USA)
Type I collagen
(Collagen alpha-1(I) chain)
Monoclonal mouse IgG1
(ab90395, Abcam, Cambridge MA, USA)
Type X collagen
(Collagen alpha-1(X) chain)
Monoclonal mouse IgM
(C7974,Sigma Aldrich, Saint Louis MO, USA)merged using the photomerge tool of Adobe Photoshop CS5
Extended Version 12.0.4 (Adobe Systems, San Jose CA, USA)without
allowing for scaling or rotational changes. Each composed photo-
micrograph was revised manually to ensure correct alignment, if
necessary. The ﬁnal images that were used for the histological
scoring provided an overview over the whole cartilage surface and
the former lesion, with the possibility to zoom in on important
details.
ICRS II histological scoring and histomorphometry
ICRS II scoringwas performed by three independent and blinded
readers (AS, FG, MK). Brieﬂy, this semiquantitative scoring system
evaluates 14 parameters regarding chondrocyte phenotype,
biochemical matrix properties and tissue structure. Scoring is
performed using a visual analogue scale ranging from 0 to 100, with
100 indicating ideal cartilage features19,20. Scores were averaged
between readers and interreader correlations were calculated.
Scoring of the parameter matrix staining could not be performed,
because glycosaminoglycan detection was not possible in repair
and native cartilage using alcian blue, fast-green/safranin O or
immunhistochemical staining for chondroitin sulphate-4 and
aggrecan, most probably due to the long ﬁxation period22.
Histomorphometry was performed using Adobe Photoshop CS5
Extended Version 12.0.4 (Adobe Systems). The pre-interventional
cartilage area was deﬁned as region of interest and named chon-
dral defect area, which was measured by drawing Bezier-curves
(unpublished protocol available on request) as projections of sub-
chondral bone interface and cartilage surface with lateral bound-
aries perpendicular to the joint surface. Within the deﬁned
chondral defect area, the area of positive type II collagen staining
was manually labelled without blinding (JS). Histomorphometric
results are displayed as type II collagen positive area (%) and were
calculated as (area of type II collagen positive staining/chondral
defect area)  100.
Statistical methods
To gauge the reliability of the scoring method, the correlation
between observers was determined for each assessed parameter,
using SPSS Statistics Version 19 (IBM, Armonk NY, USA). Pearson's
r > 0.6 was considered as high correlation between readers, r > 0.5
as moderate correlation and r < 0.5 as low correlation (Table II).
Group means and corresponding 95% conﬁdence intervals (95%
CI) were estimated using a linear mixed model. This model ac-
counts for a possible correlation of the observations that were
made in the left and right knee within one animal (proc mixed
function of SAS, SAS Institute, Cary, NC, USA) (Table III). The linear
mixedmodel was also used to obtain point estimates describing the
difference between the groups and corresponding P values (lme
function of the NMLE package23 in R version 3.1.0.; P values are
included in Table III). Differences were considered as statistically
signiﬁcant, when P < 0.05.retrieval methods for the evaluation of repair cartilage collagens using
Concentration/dilution Antigen retrieval
2.5 mg/ml Predigestion with 1 mg/mL pepsin
(SigmaeAldrich, Schnelldorf, Germany)
1:200 dilution Predigestion with 5 mg/ml pronase
(Serva Electrophoresis, Heidelberg, Germany)
10 mg/ml Predigestion with 0.25% trypsin
(SigmaeAldrich, Schnelldorf, Germany
Table II
Correlation of the ICRS II scores between the readers. The scoring was performed by
three independent and blinded readers. The correlation is displayed using Pearson's
r and based on the assessment of 34 knee joints (including knees obtained earlier
than the 13 week time-point that described in this report). The correlation was not
assessed for the parameter matrix staining, since semiquantitative scoring was not
possible, as explained in the Methods sections.
ICRS II parameter Reader 1 vs 2 Reader 1 vs 3 Reader 2 vs 3
High correlation
3. Cell morphology 0.888 0.872 0.860
5. Surface architecture 0.776 0.774 0.818
7. Formation of a tidemark 0.745 0.784 0.676
8. Subchondral bone abnormalities 0.802 0.679 0.741
10. Abnormal calciﬁcation 0.853 0.786 0.723
12. Surface/superﬁcial assessment 0.830 0.783 0.693
13. Mid/deep zone assessment 0.894 0.881 0.853
14. Overall assessment 0.890 0.930 0.926
Moderate correlation
1. Tissue morphology 0.569 0.818 0.545
6. Basal integration 0.558 0.514 0.561
11. Vascularization 0.567 0.705 0.638
Low correlation
4. Chondrocyte clustering 0.640 0.195 0.017
9. Inﬂammation 0.136 0.523 0.107
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Qualitative assessment of neo-cartilage tissues
At 13 weeks after surgery most of the BMP2 (four of six obser-
vations) and all of the IHH (eight of eight observations) treated joints
showed hyaline-like cartilage repair, while the GFP control joints
(six of six) showed repair tissue of inferior quality in the histological
assessment. In two BMP2 treated joints severe intralesional bone
formation (Fig. 2) was observed, whereas no intralesional bone
formation was observed in any IHH treated joints or GFP controls.
The joints with severe intralesional bone formation exhibited most
of the following characteristics: Osseous repair tissue over the pre-
interventional cartilage surface, absence of a cartilage cover, few or
absent type II collagen positive repair tissue and presence of strong
type X collagen deposition in the repair tissue (Fig. 2).Table III
The repair results of IHH or BMP2 treatment and the GFP control at 13 weeks after surgery
ICRS II parameter, as well as the type II collagen positive area (percentage of the initial cho
cartilage features or type II collagen deposition throughout the whole area of the former c
the observed group differences between IHH treatment (eight observations (obs.)) and GF
The utilized model is accounting for possible correlations of the bilateral observations o
GFP (n ¼ 3; 6 obs.) IH
Primary outcomes
Type II collagen positive area (% of defect) 52.2 (26.4, 78.0) 70
ICRS II e 14. Overall assessment 34.0 (2.9, 65.1) 67
Secondary outcomes
ICRS II e 1. Tissue morphology 25.0 (5.6, 44.4) 46
ICRS II e 2. Matrix staining n.a. n.
ICRS II e 3. Cell morphology 41.8 (11.9, 71.8) 65
ICRS II e 4. Chondrocyte clustering 57.5 (43.5, 71.5) 78
ICRS II e 5. Surface architecture 44.2 (19.8, 68.6) 80
ICRS II e 6. Basal integration 65.1 (44.3, 85.8) 84
ICRS II e 7. Formation of a tidemark 24.9 (3.9, 45.9) 56
ICRS II e 8. Subchondral bone abnormalities 39.1 (16.3, 61.9) 69
ICRS II e 9. Inﬂammation 83.1 (72.2, 93.9) 10
ICRS II e 10. Abnormal calciﬁcation 58.2 (27.8, 88.6) 75
ICRS II e 11. Vascularization 59.7 (34.8, 84.6) 75
ICRS II e 12. Surface/superﬁcial assessment 37.2 (10.4, 64.0) 60
ICRS II e 13. Mid/deep zone assessment 34.2 (3.1, 65.3) 69
* Indicates a P value < 0.05.Correlation between observers
A high correlation between the three observers was found
regarding the ICRS II parameter overall assessment (primary
outcome) and the secondary outcomes cell morphology, surface
architecture, formation of a tidemark, subchondral bone abnormal-
ities, abnormal calciﬁcations, surface/superﬁcial assessment and mid/
deep zone assessment (Table II). Scores correlated moderately be-
tween observers for the parameters tissue morphology, basal inte-
gration and vascularization. Low correlations are only observed for
chondrocyte clustering and inﬂammation, precluding conclusions
regarding these features of cartilage repair tissue in this report.
Primary outcomes: ICRS II overall assessment and type II collagen
positive area (%)
After 13 weeks, IHH and BMP2 treated joints demonstrated
higher scores in the ICRS II overall assessment parameter, when
compared to GFP controls: þ33.0 (0.4, 66.4; representing the 95%
CI) points for IHH and þ8.5 (26.6, 43.7) points for BMP2. Both
effects did not reach the pre-speciﬁed level of statistical signiﬁ-
cance (P ¼ 0.052 and 0.537, respectively). IHH resulted in an
increased deposition of type II collagen throughout the defect area,
while the BMP2 group did not differ from the GFP controls: þ18.7
(4.5, 42.0) points for IHH and þ0.0 (29.7, 29.8) points for BMP2.
The increased deposition was not considered as statistically sig-
niﬁcant (P¼ 0.093). The observedmeans and 95% CI of all groups, as
well as the P values for the comparison of each treatment group
with the control group is available in Table III and plotted in Fig. 3.
Secondary outcomes: ICRS II parameters at 13 weeks after surgery
In the comparison of BMP2with the control group, no signiﬁcant
differences were observed in any ICRS II parameter. In contrast, IHH
resulted in higher scores than controls in all of the assessed pa-
rameters, reaching the level of statistical signiﬁcance in ﬁve out of
the remaining 12 assessed parameters. Namely, a 21.5 (3.6, 39.4)
points increased score for the parameter tissue morphology was
observed, as well as þ21.0 (6.4, 35.7) for chondrocyte
clustering, þ31.2 (0.8, 61.5) for formation of a tidemark, þ17.3 (0.2,are displayed as group means and 95% CI (lower limit, upper limit) of each assessed
ndral defect area, as assessed by histomorphometry). A score of 100 indicates hyaline
hondral defect. A linear mixed model was used to determine the signiﬁcance level of
P controls (six obs.), as well as between BMP2 treatment (six obs.) and GFP controls.
btained from the independent animals (n shown in respective columns)
H (n ¼ 4; 8 obs.) P BMP2 (n ¼ 3; 6 obs.) P
.9 (48.6, 93.3) 0.093 52.2 (26.4, 78.0) 0.999
.0 (40.1, 94.0) 0.052 51.1 (19.9, 82.2) 0.537
.5 (29.7, 63.3) 0.027* 43.9 (24.5, 63.3) 0.287
a. n.a.
.4 (39.5, 91.3) 0.104 53.1 (23.2, 83.0) 0.666
.5 (66.4, 90.7) 0.014* 60.6 (46.5, 74.6) 0.797
.6 (59.5, 101.7) 0.055 67.7 (43.3, 92.1) 0.279
.6 (66.6, 102.5) 0.122 74.7 (53.9, 95.4) 0.583
.0 (37.8, 74.3) 0.046* 49.9 (28.9, 70.9) 0.179
.4 (49.7, 89.1) 0.077 63.3 (40.5, 86.0) 0.199
0.0 (90.6, 109.4) 0.106 96.7 (85.8, 107.6) 0.256
.5 (49.2, 101.8) 0.048* 52.3 (21.9, 82.7) 0.821
.8 (54.2, 97.3) 0.172 54.9 (30.0, 79.8) 0.821
.8 (37.6, 84.1) 0.116 57.3 (30.5, 84.1) 0.417
.1 (42.2, 96.0) 0.031* 47.6 (16.5, 78.6) 0.621
Fig. 2. Intralesional bone formation after BMP2 gene transfer. HE staining (aec), type II collagen immunohistochemical staining (def), type I collagen (gei), type X collagen (jel) and
negative control of type X collagen staining (meo) depicting the intralesional bone formation observed 13 weeks after BMP2 treatment. The depicted joint is demonstrating bone
formation over the level of the pre-interventional surface (e), absence of type II collagen in the defect area (e), strong type X collagen deposition in the few remaining cartilage isles
(as highlighted by the arrow in l). Note the strong type X collagen deposition in the adjacent cartilage (arrow in j), where concomitant chondrocyte hypertrophy can be observed
(arrow in a). Bar representing 1 mm in panorama views (b, e, h, k, n) and 500 mm in close-up views (a, c, d, f, g, i, j, l, m, o).
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the mid/deep zone assessment (Table III, Fig. 3).
Detection of chondrocyte hypertrophy markers
Using immunohistochemistry, we observed a pericellular
pattern of type X collagen deposition in all groups [Fig. 4(p)e(t),
Fig. 5(p)e(t)]. Markedly higher type X collagen depositionwas only
observed in joints with severe intralesional bone formation after
BMP2 treatment [Fig. 2 (j)e(l)].Discussion
This experiment is the ﬁrst to assess the efﬁcacy of IHH to induce
hyaline cartilage repair of osteochondral lesions in vivo. Speciﬁcally,
we have conﬁrmed our hypothesis that direct adenoviral gene
transfer of IHH into osteochondral defects, using autologous vector-
laden bone marrow coagulates, results in higher histological repair
cartilage quality (as assessed with the ICRS II histological scoring
system19) and higher type II collagen deposition, than the transfer
of non-chondrogenic GFP, while we reject our hypothesis regarding
Fig. 3. Histological repair cartilage quality at 13 weeks after the treatment with BMP2, IHH or the transfer of non-chondrogenic GFP. Dot-plots depicting the results in 12 of the 14
assessed parameters (chondrocyte clustering and inﬂammation is not shown, due to the low correlation between the three observers in those parameters). Depicted are bilateral
observations made from the left and the right knee joint of n ¼ 3, 4 and 3 independent animals for GFP, IHH and BMP2, respectively. Each dot represents one joint; both joints of each
animal were allocated to the same treatment group. Horizontal bars represent the group means, vertical bars the 95% CI. The intervals were estimated using a linear mixed model
accounting for possible correlations between both knees of each animal. While the observed difference in the primary outcomes (Type II collagen positive area (%) and the ICRS II
parameter 14. overall assessment) was not considered as statistically signiﬁcant, IHH was signiﬁcantly superior to GFP in the ICRS II parameters 1. Tissue morphology, 7. Tidemark
formation, 10. Abnormal calciﬁcation and 13. Mid/deep zone assessment. BMP2 treated joints were not signiﬁcantly different from the GFP controls.
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that IHH gene transfer results in increased scores throughout all of
the assessed parameters, when compared to controls, while BMP2
did not. Though higher scores have been consistently observedafter IHH transfer throughout all parameters, the conventional
levels of statistical signiﬁcance were not achieved for the desig-
nated primary outcomes (P ¼ 0.052 and P ¼ 0.093 for the ICRS II
overall assessment parameter and the type II collagen
Fig. 4. Histological analyses of the BMP2 treatment and GFP control group at 13 weeks. HE staining (aee), type II collagen immunohistochemical staining (fej), type I collagen (keo)
and type X collagen (pet) of the BMP2 treatment and GFP control group 13 weeks after surgery. The HE stain depicts ﬁbrocartilaginous repair tissue in the GFP control group (b, c),
which is conﬁrmed by the presence of type I collagen (l, m) and reduced type II collagen (g, h) throughout large parts of the tissue. In contrast the BMP2 treated joint is demonstrating
hyaline-like features in the HE staining (d, e), presence of type II collagen throughout the whole repair cartilage (i, j) and few concomitant type I cartilage deposition (highlighted by
the arrow in o). In general type X collagen deposition as a marker for chondrocyte hypertrophy is observed in a pericellular manner (indicated by arrows in p, r, t). The deposition
appears to be slightly increased in the BMP2 treatment groups in the shown specimens, but no substantial differences are observed between the native cartilage and the repair
cartilage of GFP controls and BMP2 treated joints (pet). Bar representing 1.5 mm in panorama views (b, d, g, i, l, n, q, s) and 500 mm in close-up views (a,c, e, f, h, j, k, m, o, p, r, t).
J.T. Sieker et al. / Osteoarthritis and Cartilage 23 (2015) 433e442 439histomorphometry, respectively), thus the appropriate caution
needs to be warranted when generalizing the here observed effects
on those parameters. However, several effects on the parameters
designated as secondary outcomes were considered to be statisti-
cally signiﬁcant (P < 0.05). In summary, we have observed an
improved tissue morphology (assessed by polarized light micro-
scopy), tidemark formation, mid and deep zone morphology, as
well as reduced abnormal calciﬁcations after IHH gene transfer. In
spite of the exploratory character of this experiment we did not
correct for the testing of multiple hypotheses. We further assessed
the efﬁcacy of BMP2 gene transfer, which has been previously
described to increase repair cartilage quality in vivo (using recom-
binant Escherichia coli-derived protein or other gene transfer sys-
tems)7e9. We observed a high variance in the results after BMP2
gene transfer, ranging from hyaline-like cartilage to severe intra-
lesional bone formation. In spite of the substantial overlap with the
results of the control group, we were not able to replicate the
beneﬁcial effect of BMP2 on cartilage repair quality that has been
observed by other authors7e9.
The primary objective of this study was to prove the concept
that IHH can be used as an alternative to BMP2 or other TGF-b su-
perfamily members. Such alternatives might ultimately allow to
induce chondrogenesis through signaling pathways that do not
induce chondrocyte hypertrophy and subsequent deterioration ofthe repair results. This study was limited to the histological
assessment of the tissue morphology (supplemented with polar-
ized light microscopy to describe the organization of the collagen
ﬁbres) and the collagen composition using immunohistochemistry
to detect type I, type II and type X collagen. An assessment of the
matrix glycosaminoglycan content could unfortunately not be
performed despite comprehensive efforts, due to an extensive ﬁx-
ation and demineralization of the samples (see Hoemann et al. for
detailed recommendations on histoprocessing of various osteo-
chondral samples20). Though collagen composition and organiza-
tion are important for the mechanical properties of repair cartilage
tissue they are not established surrogate markers for the actual
mechanical properties, which to date can only be evaluated by
biomechanical testing (such as indentation). Further, the sole his-
tological assessment is limited to the reviewed slides and do not
necessarily depict the tissue quality throughout the defect. Though
valuable, we did not perform biomechanical testing in order to
ensure the sample integrity for the histological analysis. Likewise,
biochemical and molecular-biological assays are highly valuable to
determine the cell types involved in the repair process, to deter-
mine the duration of transgene expression, as well as the effects of
the delivered gene on the expression of target genes (such as those
encoding for collagens and proteoglycans). However, those assays
would again compromise the histological assessment and the
Fig. 5. Histological analyses of the IHH treatment and GFP control group at 13 weeks. HE staining (aee), type II collagen immunohistochemical staining (fej), type I collagen (keo)
and type X collagen (pet) of the IHH treatment and GFP control group 13 weeks after surgery. The HE stain shows ﬁbrocartilaginous repair tissue in the right half of the defect that
has received GFP gene transfer (b, c), which is conﬁrmed by the presence of type I collagen in the respective area (highlighted by the arrow in l) and a concomitantly reduced type II
collagen deposition (arrow in g). In contrast the IHH treated joint is demonstrating hyaline-like features in the HE staining (d, e), presence of type II collagen throughout the whole
repair cartilage (i, j) and absence of type I cartilage deposition (n, o). The depicted specimen of the IHH treatment group is demonstrating an impaired reconstitution of the
subchondral bone (arrows in n), which was not a consistent ﬁnding in the other IHH specimens, nor reﬂected in the scores of the ICRS II parameter subchondral bone abnormalities/
marrow ﬁbrosis. Regarding the deposition of the chondrocyte hypertrophy marker type X collagen, no substantial differences are observed between the repair cartilage of GFP
controls and IHH treated joints (r, t). Type X collagen was generally deposited in a pericellular manner (arrows in r, t). Bar representing 1.5 mm in panorama views (b, d, g, i, l, n, q, s)
and 500 mm in close-up views (a, c, e, f, h, j, k, m, o, p, r, t).
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hardly be justiﬁable without a proof of IHH's in vivo efﬁcacy. Now,
after this proof of concept, detailed in vivo studies to replicate our
ﬁndings and to address the underlying mechanisms of IHH induced
cartilage repair are justiﬁed.Vector-laden bone marrow coagulates for direct gene transfer into
cartilage defects
The utilized gene transfer system was previously shown to be
effective for direct gene transfer into osteochondral defects, using
marker genes encoding for ﬁreﬂy luciferase, beta-galactosidase and
GFP16. Though being effective without the addition of cells, this
system does not allow to adjust the cell count. The number of
nucleated cells tends to vary greatly between different bone
marrow aspirations from the same animal, but not between co-
agulates aliquoted from the same aspiration16. Therefore, only co-
agulates from the initial aspirates were used for our experiments.
Pascher et al. described, that the differences in in vitro transgene
expression reﬂect the number of nucleated cells available for ge-
netic modiﬁcation in each sample16. The observed intralesional
bone formation might just resemble the response to a high BMP2transgene expression in the respective knee joints. Unfortunately,
in vivo transgene expression, nor SMAD or MAP kinase activation
could be assessed within this experiment in order to maintain the
integrity of the tissue for the histological analysis. After vector-
laden bone marrow coagulates have been characterized by
Pascher et al. using marker genes16, Ivkovic et al. demonstrated the
feasibility of this system to deliver chondrogenic genes into chon-
dral defects in a sheepmodel, utilizing adenoviral vectors to deliver
TGFB1 cDNA (encoding TGF b-1)17. TGFB1 gene transfer was shown
to result in a substantially higher type II collagen deposition than
GFP controls. However, an extensive type I collagen deposition
indicated ﬁbrocartilaginous repair17. In summary, vector-laden
bone marrow coagulates resemble an effective system for preclin-
ical evaluation of chondrogenic agents, although TGFB1 vector-
laden bone marrow coagulates were not capable to fully restore
histological cartilage quality in an ovine large animal model17.BMP-2 and IHH for articular cartilage repair
Though the proof of IHH's efﬁcacy was the primary objective of
this experiment, the attractiveness of IHH for further development
towards clinical application is based on the potentially reduced rate
J.T. Sieker et al. / Osteoarthritis and Cartilage 23 (2015) 433e442 441for adverse events which was observed for members of the TGF-b
superfamily, including ﬁbrosis of the synovial membrane, chon-
drocyte hypertrophy and consecutive osteophyte formation24e26.
Speciﬁcally, the direct gene transfer of TGFB1 to synovial lining cells
by intraarticular injection of adenoviral vectors resulted in ﬁbrosis
and ectopic chondrogenesis in native and arthritic leporine knee
joints24, as well as in native knee joints of immunocompromised
rats25. Using a method of indirect in vivo gene therapy, Gelse et al.
transplanted perichondrial mesenchymal stromal cells after ex vivo
transduction with adenoviral vectors carrying BMP2 genes into
chondral defects of rat knees26. Even though an indirect method of
gene transfer was used, dislocated cells expressing BMP2 induced
osteophyte formation in 15 of the 16 treated joints26. Using a pro-
tein based delivery of recombinant human BMP-2 in combination
with a collagen matrix into leporine chondral defects resulted in no
substantial difference in the rate of osteophyte formation27. In this
experiment we observed severe osteophyte formation in two of the
6 BMP2 treated joints. Therefore, the results presented here, sup-
port the increased risk for intraarticular bone formation after BMP2
gene transfer into articular cartilage lesions. To further explore
differences in IHH and BMP2 induced chondrogenesis, we have
performed the immunolocalization of type X collagen as a marker
of chondrocyte hypertrophy. We have only observed a marked type
X collagen deposition in the BMP2 treated joints with severe
intralesional bone formation, conﬁrming previous in vitro experi-
ments which described the increased expression of hypertrophy
markers after BMP2 treatment of multipotent cells6,12,28. We
recommend caution towards the application of BMP-2 or BMP2
gene transfer for cartilage repair due to the risk of osteophyte for-
mation, particularly in conjunction with marrow stimulating
techniques, which has been recommended previously29. One
possible strategy to counter these risks, is the combination of BMP-
2 with growth factors that mitigate hypertrophic differentiation28.
In contrast, the strategy proposed here aims to omit the induction
of pathways that are activated by TGF-b superfamily members and
to induce chondrogenic differentiation via pathways that don't
trigger hypertrophic differentiation of chondrocytes and consecu-
tive matrix mineralization.
This is the ﬁrst description of IHH's efﬁcacy to improve histo-
logical repair cartilage quality in vivo. Hedgehog family members
have important functions during development of various tissues,
whereas IHH appears particularly promising for the stimulation of
in vivo chondrogenesis due to it's regulatory function in the growth
plate cartilage14.
Based on this experiment we conclude that IHH is capable to
induce cartilage repair in vivo. However, future studies are needed
to assess the underlying mechanisms of these ﬁndings in the
context of in vivo cartilage repair. Additional biomechanical,
biochemical and molecular genetic assays need to be utilized to
comprehensively characterize the achieved neo-cartilage quality,
and whether IHH can reduce the expression levels of hypertrophy
markers in vivo, to the same degree as they were previously shown
to be reduced in vitro13. Additionally, the effect of IHH protein on
the expression of further target genes needs to be assessed,
including anti-hypertrophic genes (i.e., PTHLH, encoding para-
thyroid hormone-related protein), anti-osteogenic genes (i.e., SOST,
encoding for sclerostin) andmarkers of chondrocyte differentiation
(i.e., genes encoding for type II collagen and proteoglycans).
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